Year All202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998 BioCryst to Report Third Quarter 2024 Financial Results on November 4 Oct 21, 2024 Read More BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat) Oct 14, 2024 Read More BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting Oct 10, 2024 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Oct 03, 2024 Read More BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome Oct 02, 2024 Read More U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile Sep 30, 2024 Read More BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium Sep 06, 2024 Read More BioCryst Appoints Dr. Donald Fong Chief Medical Officer Sep 05, 2024 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 04, 2024 Read More BioCryst to Present at Upcoming Investor Conferences Aug 22, 2024 Read More
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat) Oct 14, 2024 Read More
BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting Oct 10, 2024 Read More
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome Oct 02, 2024 Read More
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile Sep 30, 2024 Read More
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium Sep 06, 2024 Read More